aka Tandutinib is Takeda’s Ph2 FLT3, cKIT, PDGFR inhibitor Blood.
Archive for the ‘Flt3’ Category
TG-101348
Posted by kinasepro on December 7, 2007
Targegen’s got a press release:
Plans to initiate a multi-center clinical trial of TG101348, an internally discovered, oral, potent, and highly selective JAK2 inhibitor in January, 2008
A poster at ASH:
…Dual-Acting JAK2/FLT3 Small Molecule Kinase Inhibitor for the Treatment of AML
and some pyrimidines in WO/2007/053452:
Posted in biotech, clinical, Flt3, JAK | Leave a Comment »
News of the day
Posted by kinasepro on November 14, 2007
- Ambit grabs 50M in a Series D. Their Lead is AC-220 a ph1 selective Flt3 compound. In WO/2007/109120?
![O=C(N([H])C2=CC=C(C3=CN4C(SC5=CC(N6CCN(C)CC6)=CC=C45)=N3)C=C2)N([H])C1=NOC(C(C)(C)C)=C1](http://img107.imageshack.us/img107/5254/ambitgo4.jpg)
aetiology and limited data in: WO/2005/048953
- Rigel tacks on 3M for the Japanese rights to R-763.
R-788 (Fostamatinib disodium)
Posted by kinasepro on November 9, 2007
R-788 is Rigel’s SYK / Flt3 inhibiting prodrug of R-406, and despite a positive sounding press release on their Ph2 ITP study, the market is reacting negatively so far by knocking 20% off of the stock price.
the name suggests disodium.
Posted in Flt3, Rigel, SYK | 15 Comments »
ABT-869
Posted by kinasepro on June 26, 2007
Phase 2 on the doorstep, Genentech and Abbott just announced a collaboration to include development of the compound w/ backups. No terms disclosed…
Vegf, Flt3, Tie2, c-FMS, Pdgf, c-kit yadda yadda
Posted in Abbott, c-fms, Flt3, Genentech, PDGFR, TIE2, VEGF | Leave a Comment »
ENMD-981693
Posted by kinasepro on June 1, 2007
So Entremed is over in Boston stumping for their Aurora inhibitor and they happened to drop the MW and cLogP:
Only two compounds from WO/2007/041358 fit that bill. That one, and the Z isomer.
Posted in Aurora, biotech, Flt3, multi-target | 4 Comments »
Lestaurtinib
Posted by kinasepro on May 28, 2007
![O=C1NCC2=C1C3=C4N([C@H]5C[C@](O)([C@](C)(N6C4=C2C7=C6C=CC=C7)O5)CO)C8=C3C=CC=C8](http://img47.imageshack.us/img47/3384/cp701vh2.jpg)
Lestaurtinib / CEP-701 is currently in trials for a handful of indications and first appeared in WO/1988/07045 (US,4,923,986) via Kyowa Hakko Kogyo. The series was first described as a group of PKC inhibitors, but later came this ’98 press release: (emphasis mine)
CEP-701 is one of a series of specific receptor trk kinase inhibitor derived from the indolocarbazole K252a, which was originally synthesized by Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan
Posted in c-Met, Cephalon, Flt3, JAK, Trk, VEGF | 3 Comments »
US20070004763
Posted by kinasepro on January 5, 2007
These are part of a Flt3 and/or TrkB series which JnJ has been putting a beat down on lately.
Posted in Flt3, J&J, Trk | Leave a Comment »
US20060281764
Posted by kinasepro on December 16, 2006
WTF J&J, Oxime-aldehydes? FLT3, TRKb, cKit inhibitors… Shinogi has some related EGF compounds: WO2006106721, and there’s a Biorg Med Chem Lett with the motif in CDK so its not unheard of. Quinazoline isosteres… Cool.
![O=C(NC1=CC=C(C(C)C)C=C1)CC2CN(C3=NC=NC(N([H])[H])=C3/C=N/OC)CC2](http://img282.imageshack.us/img282/6295/jnjjy2.jpg)
Update >> There’s a couple other relatives that make this a family of applications which all published last Thursday:
This looks like the primary series, and the aniline appears to dial in TRKB – albeit not all that dramatically: US20060281772
US20060281768
Hmm… is LG293 TRKb?
Posted in c-Kit, Flt3, J&J | 2 Comments »
